Lynch syndrome is an inherited condition affecting 1 in 300 people that causes lifetime cancer risk of up to 80%[1] The ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 5.1% in the afternoon session after the stock's ...

Moderna secures up to $50 million to develop an Ebola vaccine.

When used alongside Merck’s Keytruda, Moderna’s personalized cancer vaccine halved the risk of death or disease recurrence in ...

CEPI is committing up to $50 million to support Moderna's vaccine candidate for the strain with no approved shot ...

With a market cap of $19.5 billion, Moderna, Inc. (MRNA) is a biotechnology company focused on developing medicines and ...

eCommerce Powered by FFF Enterprises™ delivers an enhanced ordering experience for Moderna customers. Built on BioSupply®, FFF Enterprises’ proprietary ecommerce platform, the Moderna Direct site ...

Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already been a powerful 2026 ...

Alex Hogan is STAT’s senior multimedia producer and host of STATus Report, STAT’s weekly video series. You can follow him on Bluesky. The story of the biotech company Moderna almost reads like a ...

AFP / Moderna shares are surging after a report the drugmaker confirmed it's working on a potential hantavirus vaccine. Several people have tested positive for the rare hantavirus on the cruise ship ...

Moderna’s mRNA flu vaccine gave more protection against illness than the standard flu shot in a phase 3 clinical trial, according to published results.

Under the plans, CEPI has committed up to $50 million to US-based Moderna for preclinical development and Phase 1 clinical ...